Core Insights - Kinder Morgan Inc. (KMI) is scheduled to report its fourth-quarter 2025 results on January 21, with earnings per share (EPS) estimated at 36 cents and revenues at $4.4 billion, indicating a year-over-year increase in both metrics [1][8]. Financial Performance - In the previous quarter, KMI reported adjusted earnings of 29 cents per share, aligning with the Zacks Consensus Estimate, primarily driven by natural gas pipeline operations [2]. - The Zacks Consensus Estimate for fourth-quarter revenues of $4.4 billion suggests a 10.9% increase from the previous year's figure [3]. Revenue and Earnings Projections - The estimated revenue from natural gas pipelines for the fourth quarter is projected at $2,928 million, up from $2,437 million in the same quarter last year [5]. - The expected earnings from natural gas pipelines are estimated at $1,564 million, an increase from $1,392 million in the prior-year quarter [5]. Operational Context - Kinder Morgan operates an extensive natural gas pipeline network of approximately 66,000 miles, transporting nearly 40% of the natural gas produced in the United States, which supports steady cash flows due to fee-based contracts [4]. Earnings Expectations - KMI has an Earnings ESP of 0.00%, indicating a lower likelihood of an earnings beat for the upcoming quarter [6][8]. - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [6].

Core Viewpoint - Northern Trust Corporation (NTRS) is expected to report increased earnings and revenues for the fourth quarter and 2025, with results influenced by net interest income growth and asset management increases [1][8]. Financial Performance - In the last reported quarter, NTRS experienced an earnings surprise, benefiting from a rise in net interest income and increases in total assets under custody and management, although elevated expenses and reduced fee income were noted as concerns [2]. - The Zacks Consensus Estimate for NTRS' fourth-quarter earnings is $2.37 per share, reflecting a 4.9% increase year-over-year, while revenue estimates stand at $2.07 billion, indicating a 5.8% rise [3]. - The expected net interest income (NII) for the fourth quarter is $600.8 million, representing a 6.6% year-over-year increase, supported by stabilizing funding costs following recent Federal Reserve interest rate cuts [3][4]. Asset Management and Fees - The average earning assets are estimated at $142.5 billion, showing a significant 29% increase from the prior year [4]. - The Zacks Consensus Estimate for custody and fund administration fees is $488.7 million, indicating a 6.9% year-over-year rise, while investment management fees are expected to reach $167.4 million, up 6.7% from the previous year [6]. - Total wealth management fees are estimated at $580.7 million, reflecting a 6.2% increase year-over-year [6]. Operating Income and Expenses - Other operating income is projected at $59.2 million, which represents a 1.1% decline year-over-year [7]. - Total fee income is estimated at $1.47 billion, suggesting a 5% increase from the prior-year quarter [9]. - Elevated expenses are anticipated due to higher compensation costs and ongoing investments in technology infrastructure [9]. Asset Quality - Non-performing assets are expected to reach $82.9 million, indicating a significant 48% increase year-over-year, attributed to a slowdown in job growth potentially impacting consumer demand [10]. Earnings Prediction - The current Earnings ESP for NTRS is -0.38%, indicating that the model does not predict an earnings beat for this quarter [11]. The company holds a Zacks Rank of 3, suggesting a neutral outlook [12].

Core Viewpoint - Teledyne Technologies (TDY) is set to report its fourth-quarter 2025 results on January 21, 2026, with expectations of a year-over-year increase in earnings and revenues, driven by recent acquisitions and solid sales in various segments [1][5][9]. Group 1: Upcoming Results and Expectations - The acquisition of TransponderTech from Saab AB is anticipated to enhance TDY's performance in Q4 2025 by expanding its maritime technology offerings, which include Automatic Identification System and Global Navigation Satellite System solutions [2]. - The Zacks Consensus Estimate for TDY's earnings is $5.83 per share, reflecting a 5.6% increase year-over-year, while revenues are expected to reach $1.57 billion, indicating a 4.5% improvement [5][9]. Group 2: Segment Performance - The Aerospace & Defense Electronics unit is likely to see improved top-line performance due to solid organic sales of defense electronics products and growth from recent acquisitions [3]. - The Instrumentation segment is expected to benefit from increased sales of gas detection products and marine instrumentation [3]. - The Digital Imaging unit is projected to experience growth driven by higher sales of commercial infrared imaging components and unmanned air systems [4]. Group 3: Earnings Prediction Model - The current Earnings ESP for TDY is -0.52%, indicating that the model does not predict an earnings beat for this reporting cycle [6]. - TDY holds a Zacks Rank of 2, suggesting a "Buy" rating, which reflects a positive outlook despite the earnings prediction [7].

Group 1 - Moderna, Inc. is a leading biotechnology company known for its mRNA technology, particularly in COVID-19 vaccine development, competing with Pfizer and BioNTech [1] - Citigroup has updated its rating for Moderna to "Neutral," indicating that investors should hold onto the stock, which is currently trading at approximately $41.84 [1][5] - The stock has seen a 6.29% increase, with a daily trading range between $40.55 and $42.30, and a market capitalization of around $16.35 billion [4][5] Group 2 - Investors often focus on stocks that are expected to exceed quarterly earnings estimates, as these can significantly influence stock prices [2] - The Zacks Earnings ESP tool is utilized to identify potential earnings surprises by analyzing recent analyst revisions, which can help investors enhance their returns [3]

Core Viewpoint - Alcoa Corporation is set to report its fourth-quarter 2025 results on January 22, with earnings estimates showing an 18.8% increase over the past 60 days, but a projected decline of 8.7% year-over-year in earnings and a 7% decline in revenues [1][7]. Earnings Estimates - The Zacks Consensus Estimate for earnings is currently at 95 cents per share, with revenues expected to be $3.24 billion [1]. - The earnings surprise history shows that Alcoa has consistently outperformed estimates, with an average surprise of 39.3% over the last four quarters [2]. Earnings Prediction - Alcoa has an Earnings ESP of +0.53%, with the Most Accurate Estimate at 96 cents per share, indicating a favorable outlook for an earnings beat [4][3]. Segment Performance - The Aluminum segment is projected to see total sales of $2.45 billion, reflecting a 29% increase year-over-year, driven by demand in electrical and packaging markets [5]. - Conversely, the Alumina segment is expected to report total sales of $1.32 billion, indicating a 46% decline from the previous year due to lower shipments and trading activity [6]. Strategic Developments - Recent partnerships and acquisitions, including a joint venture for the San Ciprián site and the acquisition of Alumina Limited, are expected to enhance Alcoa's production capacity and market position [8][5]. Market Performance - Alcoa's shares have increased by 54.2% over the past three months, outperforming both the Zacks Metal Products - Distribution industry and the S&P 500 [10]. Valuation Metrics - The stock is currently trading at a forward P/E ratio of 12.50X, slightly below the industry average of 12.82X, suggesting potential upside [13]. Investment Thesis - Alcoa's diversified product portfolio and strategic collaborations position it well for growth, particularly in the context of increasing demand for energy-efficient products and the impact of higher tariffs on aluminum imports [15][16].

Core Viewpoint - Citizens Financial Group, Inc. (CFG) is expected to report an increase in fourth-quarter and 2025 earnings and revenues compared to the previous year [1][10] Financial Performance Expectations - CFG's net interest income (NII) is projected to rise by 2.5-3% sequentially in Q4 2025, with a Zacks Consensus Estimate of $1.53 billion, reflecting a 2.7% increase from the prior quarter [4] - The average interest-earning assets are estimated at $199.9 billion, indicating a 1.2% rise from the previous quarter [5] - The consensus estimate for fourth-quarter earnings is $1.11 per share, representing a 30.6% increase year-over-year, while revenues are expected to reach $2.15 billion, an 8.2% rise from the previous year [15] Income Sources - Non-interest income is anticipated to be flat, with mortgage banking fees estimated at $51.5 million, a 5.1% decline from the prior quarter [7] - Trust and investment services fees are expected to increase to $96.3 million, a 3.5% rise from the previous quarter [8] - Service charge and fee revenues are projected at $114.9 million, reflecting a 2.6% increase from the prior quarter [9] - Card fees are estimated at $89.6 million, indicating a 2.9% rise from the previous quarter [11] Expense and Asset Quality Outlook - Adjusted non-interest expenses are expected to be stable or slightly up due to the opening of private banking offices and investments in technology [12] - The Zacks Consensus Estimate for non-accrual loans is pegged at $1.57 billion, indicating a sequential rise of 3.3% [13] 2025 Outlook - Management anticipates NII to rise by 3-5% from $5.6 billion in 2024, with a net interest margin (NIM) expected to be 3% [16] - Average loans are projected to decrease by 2-3% from $139.2 billion in 2024, while average earnings assets are forecasted to fall by 1% from $198.1 billion [16] - Non-interest income is expected to increase by 8-10% from $2.6 billion reported in 2024 [16] - Adjusted non-interest expenses are projected to grow by 4% from $5.1 billion in 2024 [17]

Core Viewpoint - Procter & Gamble (PG) is expected to report second-quarter fiscal 2026 results on January 22, with projected year-over-year sales growth of 1.6% to $22.23 billion, while earnings per share are anticipated to decline by 0.5% to $1.87 [1][2]. Financial Expectations - The Zacks Consensus Estimate for revenues is $22.23 billion, reflecting a 1.6% increase from the previous year [2]. - The earnings consensus is $1.87 per share, indicating a 0.5% decrease from the prior year [2]. - PG has a trailing four-quarter earnings surprise of 2.3% on average, with a 4.7% surprise in the first quarter of fiscal 2026 [3]. Earnings Prediction - The model indicates a negative Earnings ESP of -0.82% and a Zacks Rank of 4 (Sell), suggesting a lower likelihood of an earnings beat this quarter [4]. Operational Challenges - PG faces significant challenges, including elevated commodity costs, higher tariffs, and intense competition in developed markets, which are expected to pressure margins [6][10]. - The company anticipates a commodity cost headwind of $100 million after tax for fiscal 2026, impacting gross margins [8]. - Tariffs are projected to add $400 million in after-tax costs for fiscal 2026, further complicating earnings visibility [10][11]. Margin Outlook - A year-over-year core gross margin decline of 50 basis points is predicted, with core operating margins expected to fall by 80 basis points [9]. - The high-cost environment is likely to continue affecting gross margins in the upcoming quarter [8]. Sales Growth Projections - Organic sales growth is forecasted at 1% for the second quarter, with specific segments like Beauty and Health Care expected to grow by 2%, and Grooming by 4% [14]. - Fabric & Home Care and Baby, Feminine & Family Care segments are anticipated to remain flat year-over-year [14]. Strategic Initiatives - PG is focusing on restructuring, productivity initiatives, and innovation to navigate current challenges and improve agility [15][25]. - The company is rolling out major product upgrades and new formats to drive sustainable growth [13]. Stock Performance and Valuation - PG shares have declined by 6.7% over the past six months, underperforming the industry average decline of 8.4% [16][20]. - The stock is trading at a forward P/E multiple of 20.18X, above the industry average of 18.2X but below the S&P 500's average of 23.29X, indicating a premium valuation [21]. Investment Considerations - The investment appeal of PG lies in its strong brand portfolio and disciplined execution, despite near-term pressures from competitive intensity and input costs [24][25]. - Investors may prefer a cautious approach, monitoring execution on innovation and productivity initiatives, while existing shareholders might hold for stability [27].

Core Viewpoint - Truist Financial (TFC) is expected to report strong fourth-quarter and full-year 2025 results, driven by solid lending demand and net interest income (NII) growth despite recent Federal Reserve interest rate cuts [1][3][10]. Lending and Income Estimates - Demand for commercial and industrial (C&I) loans, which make up nearly 50% of TFC's total loans, was decent in the quarter, alongside solid consumer loan demand, which accounts for almost 40% [2]. - The Zacks Consensus Estimate for TFC's average earning assets is $490.4 billion, reflecting a 3.7% increase from the prior year [2]. - NII is projected to rise by 3.2% to $3.71 billion, supported by robust loan demand and lower deposit costs [3][10]. Non-Interest Income - The Zacks Consensus Estimate for non-interest income is $1.57 billion, indicating a 6.5% rise year-over-year, with significant contributions from various fee income segments [8][10]. - Service charges on deposits are estimated at $240.9 million, a 1.7% increase, while card and payment-related fees are expected to reach $231.1 million, showing marginal growth [5]. - Investment banking and trading income is projected to be $323.8 million, reflecting a year-over-year increase of 23.6% [7]. Mortgage Banking and Expenses - Mortgage banking income is expected to rise to $117.4 million, slightly up from the previous year, due to declining mortgage rates and decent refinancing activity [6]. - Non-interest expenses are anticipated to continue rising due to technology investments and inflationary pressures, with management expecting adjusted expenses to remain stable sequentially [9]. Asset Quality and Earnings Outlook - The consensus estimate for total non-accrual loans and leases is $1.87 billion, indicating a 30.6% year-over-year increase, while total non-performing assets are also expected to rise by 26.6% to $1.87 billion [11]. - The Zacks Consensus Estimate for TFC's earnings is $1.09 per share, reflecting a growth of 19.8% from the previous year, with sales projected at $5.27 billion, a 4.1% increase [14][15]. 2025 Outlook - Management anticipates revenue growth of 1.5-2.5% from adjusted revenues of $20.1 billion in 2024, with adjusted expenses expected to increase by about 1% [16].

Core Insights - Johnson & Johnson (JNJ) is set to report its fourth-quarter and full-year 2025 results on January 21, with consensus estimates for sales at $24.14 billion and earnings at $2.50 per share [1] - The earnings estimates for 2025 have slightly decreased from $10.87 to $10.83 per share, and for 2026 from $11.48 to $11.46 per share over the past 60 days [1] Earnings Estimates - Current earnings estimates for Q1, Q2, FY 2025, and FY 2026 are $2.49, $2.77, $10.83, and $11.46 respectively, showing a downward trend in estimates over the past 60 days [2] - JNJ has a history of exceeding earnings expectations, with an average earnings surprise of 3.75% over the last four quarters [2] Business Segment Performance - The Innovative Medicine segment is expected to show growth driven by key products like Darzalex, Tremfya, and Erleada, with sales estimates of $3.74 billion, $1.36 billion, and $936 million respectively [5] - The MedTech business has improved due to acquisitions and is expected to continue strong performance in cardiovascular and surgical units, with a sales estimate of $8.71 billion [10][11] Challenges and Competition - The launch of several biosimilars for Stelara has negatively impacted its sales, with an estimated decline of 1070 basis points in the third quarter and expected further decline in the fourth quarter [7] - Sales of Imbruvica are anticipated to decline due to competitive pressures and the redesign of Medicare Part D, with an estimate of $670 million [8][9] Future Outlook - JNJ plans to provide an updated financial outlook for 2026, expecting over 5% revenue growth, which is higher than the previous consensus estimate of 4.6% [12] - The company has advanced its pipeline significantly, with 10 new products expected to potentially deliver peak sales of $5 billion [22] Stock Performance and Valuation - JNJ shares have outperformed the industry, rising 48.7% over the past year compared to the industry growth of 24.1% [15] - The stock is currently trading at a price/earnings ratio of 19.01, higher than the industry average of 17.73 and above its five-year mean of 15.65 [18] Investment Considerations - JNJ's diversified business model, strong cash flows, and consistent dividend increases over 63 years make it a compelling investment despite current challenges [20][24]

Core Insights - Abbott Laboratories (ABT) is expected to report its fourth-quarter 2025 results on January 22, with adjusted earnings per share (EPS) of $1.30 in the last quarter, matching the Zacks Consensus Estimate [1] - The Zacks Consensus Estimate for revenues is $11.79 billion, indicating a 7.5% increase year-over-year, while EPS is projected to rise by 11.9% to $1.50 [2] Q4 Estimates - Revenue growth for the Diagnostics segment is anticipated to be impacted by volume-based procurement programs in China, with a projected increase of 0.8% year-over-year [3][4] - The Established Pharmaceuticals (EPD) segment is expected to show strong performance across 15 key markets, with an estimated revenue increase of 8.5% year-over-year, driven by demand in therapeutic areas such as gastroenterology and cardiometabolic [5][6] - The Medical Devices segment is projected to see a 12.5% year-over-year revenue improvement, supported by strong sales in Diabetes Care and Electrophysiology [7][13] - The Nutrition division is expected to grow by 3.3%, bolstered by new product launches in adult nutrition brands [8][15] Estimate Revision Trend - Estimates for Q4 earnings have remained unchanged at $1.50 per share over the past 30 days, indicating stability in expectations [3] Segment Performance - The Diagnostics segment's growth is likely to be sustained by global demand for routine diagnostic testing, particularly in the U.S. market [4] - The Medical Devices segment's growth is attributed to advancements in various divisions, including the launch of new products and regulatory approvals [10][12] - The Nutrition segment's growth is driven by the introduction of low-sugar formulas and new protein shakes, which are expected to enhance sales [14]